A clinical practice guideline approach to treating depression in long-term care

Journal of the American Medical Directors Association

Volumn 4, Issue 2 SUPPL., 2003, Pages

  Kaldy, Joanne ^a   Tarnove, Lorraine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIDOPA; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DOXEPIN; FLUOXETINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPRAMINE; LEVODOPA; MAPROTILINE; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; CENTRAL STIMULANT AGENT; MONOAMINE OXIDASE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; AGITATION; AKATHISIA; ANOREXIA; ANXIETY; ARTICLE; CLINICAL PRACTICE; COST OF ILLNESS; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DYSTONIA; EARLY DIAGNOSIS; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GERIATRIC CARE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; LABORATORY TEST; LONG TERM CARE; MEDICAL STAFF; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PRACTICE GUIDELINE; PREVALENCE; PSYCHOTHERAPY; QUALITY OF LIFE; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR; XEROSTOMIA; ALGORITHM; CLASSIFICATION; NURSING HOME; PATIENT CARE PLANNING; STANDARD; UNITED STATES;

AGED; ALGORITHMS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER; HUMANS; LONG-TERM CARE; MONOAMINE OXIDASE INHIBITORS; NURSING HOMES; PATIENT CARE PLANNING; PRACTICE GUIDELINES; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 0037340456     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70311-4     Document Type: Article

References (26)

1. American Medical Directors Association. Depression Clinical Practice Guideline. Columbia, MD:1996.
2. American Medical Directors Association. Pharmacotherapy Companion to the Depression Clinical Practice Guideline. Columbia, MD:1998.
3. Jeffrey SM, Feldman S. Identification and treatment of geriatric depression. J Am Soc Consult Pharmacists 2000;Suppl 3(15):1-16.
4. Tollefson GD, Holman SL. Analysis of the Hamilton Depression Rating Scale: Factors for a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int J Clin Psychopharmacol 1993;8:253-259.
5. Stapleton S. Aging, illness can mask depression in older patients. American Medical News. November 1, 1999: 22-23.
6. Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult. Arch Intern Med 1999;159:1701-1704.
7. Agency for Healthcare Quality and Research. Depression in Primary Care. Volume 1. Detection and Diagnosis. Rockville, MD: AHQR, 1994.
8. Liu B, Anderson G, Mittman N, et al. Use of selective serotonin reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303-1307.
9. Scoggin J, Nolan S. The serotonin syndrome: Recognition and management. US Pharmacist February 1998;87-94.
10. Alderman C, Seshadri P, Ben-Tovin D. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacotherapy 1996;30:1232-1234.
11. Liu B, et al. Hypoatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports. Can Med Assoc J 1996;155:519-527.
12. Newhouse PA. Use of serotonin selective reuptake inhibitors in geriatric depression. J Clin Psychiatry 1996;57(Suppl 5):12-22.
13. Hay DP, et al. Use of newer antidepressants in the elderly. Nurs Home Med 1997;5:28-40.
14. Alexopoulous GS, et al. Cornell Scale for Depression in dementia. Biol Psychiatry 1998;23:27-84.
15. Teri L, et al. Imipramine in the treatment of depressed Alzheimer's disease patients: Impact on cognition. J Gerontol 1991;46:372-377.
16. Feigher JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(Suppl A):62-68.
17. deMontigny, et al. Venlafaxine in treatment-resistance major depression: A Canadian, multicenter, open-label trial. J Clin Psychopharmacol 1999; 19:401-406.
18. Holm KJ, Markham A. Mirtazapine: A review of its use in major depression. Drugs 1999;57:607-631.
19. Preskorn SH. Selection of an antidepressant: Mirtazapine. J Clin Psychiatry 1997;58(Suppl 6):3-8.
20. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety, and tolerability of mirtazapine for the treatment of patients with major depression. J Affective Disorders 1998;51:267-285.
21. Nierenberg AA, et al. Trazodone of antidepressant-associated insomnia. Am J Psychiatry 1994;151:1069-1072.
22. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion. J Affective Disorders 1998;51:237-254.
23. Green DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinetics 1997;33:260-275.
24. Goldberg RJ. Antidepressant use in the elderly: Current status of nefazodone, venlafaxine, and moclobemide. Drugs Aging 1997;11:119-131.
25. Tuma TA. Outcome of hospital-treated depression at 4.5 years. Br J Psychiatry 2000;176:224-228.
26. Fournies FF. Why Employees Don't Do What They're Supposed to Do, and What to Do About It. Blue Ridge Summit PA: Liberty Hall Press, 1998.